Active surveillance of prostate cancer; Prostate cryotherapy; Prostate carcinogenesis; Prostate cancer
Dr. Ashley Evan Ross is an assistant professor of urology, oncology and pathology at the Johns Hopkins School of Medicine. His clinical practice focuses on prostate cancer and prostatic diseases.
He has expertise in open and robotic treatment of prostate cancer as well as in focal and salvage prostate cryotherapy and in the active surveillance of prostate cancer. Additionally, Dr. Ross has experience in the treatment of benign prostatic hyperplasia through the use of transurethral resection, laser photo-vaporization and open surgical approaches. As an active member of the Sidney Kimmel Comprehensive Cancer Center, Dr. Ross offers multidisciplinary approaches to the treatment of prostate cancer.
Dr. Ross received his undergraduate degree in biochemistry from the University of Maryland. He earned his graduate and medical degrees from the Johns Hopkins School of Medicine. Dr. Ross joined the faculty in 2012 after completing his general surgery and urology residency and fellowship at Johns Hopkins.
Dr. Ross’s research focuses on prostate carcinogenesis. His laboratory investigates molecular mechanisms that drive prostate cancer and is developing and testing novel targeted therapies for this aggressive disease. Dr. Ross is known for his discovery of how to use Relaxin 1 (RLXN1) as a tissue/urine/blood-based biomarker of high-grade prostate cancer.
Dr. Ross has been recognized with numerous awards and honors. He served as the chief resident in the Department of Urology’s residency program at Johns Hopkins. Most recently, he was recognized with a first prize for a paper presentation at the Baltimore-Washington-West Virginia Urology Resident Day. He is a member of the American Urologic Association.